Pegvaliase (Palynziq®) HTA ID: 21057
Pegvaliase is indicated for the treatment of patients with phenylketonuria aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l) despite prior management with available treatment options.
| NCPE Assessment Process | Complete |
| For further details of previous submission see: Pegvaliase (Palynziq®) HTA ID: 20001 | |
| Full re-submission received from Applicant | 18/11/2021 |
| Preliminary review sent to Applicant | 21/03/2022 |
| NCPE assessment re-commenced | 22/04/2022 |
| Preliminary review II sent to Applicant | 02/06/2022 |
| NCPE assessment re-commenced | 24/06/2022 |
| Factual accuracy check sent to Applicant | 08/08/2022 |
| NCPE assessment recommenced | 16/08/2022 |
| NCPE assessment completed | 29/09/2022 |
| NCPE assessment outcome |
The NCPE recommends that pegvaliase (Palynziq®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.